In the context of a scopolamine-induced AD rat model, observations within the hippocampus reveal that pre-treatment with VitB12 can not only effectively counter the decrease of neurexin 1 and neuroligin, and the elevation of COX-2 and activation of caspase-3 (markers employed to assess AD’s severity and progression) but also alleviate the decline of postsynaptic density protein 95 (PSD-95), a scaffold protein that regulates synaptic maturation and plasticity. The gene discussed is NRXN1; the disease is Alzheimer disease.